Eric I. Richman - 20 Sep 2023 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Director
Signature
/s/ Jason Minio, Attorney-in-Fact
Issuer symbol
GANX
Transactions as of
20 Sep 2023
Net transactions value
$0
Form type
4
Filing time
22 Sep 2023, 16:34:38 UTC
Previous filing
22 Sep 2022
Next filing
26 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GANX Common Stock Options Exercise +54,900 +25% 272,629 20 Sep 2023 Direct F1
holding GANX Common Stock 14,829 20 Sep 2023 By Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Restricted Stock Units Options Exercise $0 -54,900 -100% $0.000000* 0 20 Sep 2023 Common Stock 54,900 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2 Shares are held by the Eric I. Richman Living Trust (the "Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of his proportionate pecuniary iinterest therein.
F3 The RSUs vested fully on September 20, 2023.